|
Seminar luncheon
Developing Relevant Human Neural In Vitro Assays for CNS Safety Assessment and Drug Discovery: Challenges and Perspectives
Speakers:
Jonathan Davila PhD., CEO / Co-Founder, NeuCyte Inc.
Organizers:
Date:
2017-07-28
Time:
11:00-13:30 Pacific Time
Registration fee
(USD): Food: $0.
Location:
SF Bay Area: Foster City Crowne Plaza
Major Sponsor:
Vendor show vendors registered to date:
(5)Agilent; BioLegend; Cyprotex; JL Powers & Co; Thermo Fisher Scientific, SID
Registration: http://www.PBSS.org
Registration deadline:2017-07-26
(it will close sooner if the seating cap is reached)
About the Topic
High attrition rates of novel CNS drugs indicate that current preclinical testing is largely insufficient to support development of urgently needed therapies for millions of patients. iPSC technology and rapidly improving methods to generate functional human tissues offer new opportunities to develop novel disease relevant cell-based assays. This approach comes with high expectations but also presents many challenges. NeuCyte develops human neural in vitro platforms uniquely suited for assessing relevant complex electrophysiology readouts allowing for more reliable prediction of drug efficacy, CNS safety, and identification of neurotoxicity. In this presentation, we will provide an overview of critical considerations that need to be taken when developing human iPSC derived neural in vitro assays.
2019-12-10, In Vitro Diagnostics (IVD) & Companion Diagnostics (CDx): Guiding Clinical Trials and Patient Treatment through Precision Medicine
|
2020-01-10, All about half-life: which one should I use? (tentative title)
|
2020-01-21, Considerations for Successful Clinical Development: Fundamentals and Best Practices for Clinical Trial Design, Biostatistics, and Data Management
|
2020-02-11, Development of Drug/Device Combinations
|
2020-02-24, MS Courses by Dr. Jack Henion: Advanced LC-MS/MS (Day1) & Interpretation of MS/MS CID Spectra (Day2)
|
2020-03-09, Preclinical Models for Oncology
|
2020-03-16, Clinical Trials Essentials: An Intensive One-Week Course (register for the full week or half day sessions)
|
2020-04-10, Development of Multivalent Protein Conjugates as a Strategy to Engineer Drug Pharmacology
|
2020-05-12, Regulated Large Molecule Bioanalysis: Fundamentals, the New FDA Guidance and Beyond
|
2020-05-22, No More Undruggables: Unconventional Approaches for Drug Discovery and Design - prodrugs, PROTACS, fragment-based design, directed evolution and beyond
|
2020-06-23, Advances in Immuno-Oncology (A Joint Symposium by PBSS and BioScience Forum)
|
|
Ads (in random order)
Submit a Text Ad
($250 for 2 months)
Alturas Analytics, Inc.
Expert GLP & non-GLP LC-MS/MS & GC-MS/MS bioanalytical quantitation services of small & large molecules in any matrix. Discovery through phase IV.
|
Origin Bioanalytical Laboratory
Sacramento-based CRO for bioanalytical method development, validation, and consulting of LC-MS/MS analysis, specializing in ocular matrices
|
Pacific BioLabs
Bay Area CRO with 37 years experience in Methods Development & Validation, Bioanalysis, Toxicology, Immunogenicity, Stability Studies & Microbiology
|
Submit a Text Ad
|